FierceBiotechOriginal article
{"a":[{"_":"Merck stages expanded access to monthly HIV PrEP pill ahead of approval","$":{"href":"/pharma/merck-prepares-expanded-access-alimatravir-monthly-hiv-prep-pill-ahead-approval","hreflang":"en"}}]}
PartnershipalimatravirPositive
AI Analysis
Summary
Merck has signed voluntary licensing agreements to provide expanded access to its investigational monthly HIV PrEP pill alimatravir prior to regulatory approval, following a similar strategy employed by Gilead.
Outcome Details
Voluntary licensing agreements signed to enable expanded access ahead of regulatory submission
Importance:6/10
Sentiment:
0.60
HIV PrEPexpanded accesslicensing agreementregulatory pathwaymonthly pill
Related Companies
Read the original article
Published by FierceBiotech on July 24, 2026 9:35 AM